Acumen Pharmaceuticals, Inc.
ABOS
$2.26
-$0.03-1.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 110.44% | 117.26% | 109.33% | 154.03% | 98.92% |
| Gross Profit | -110.44% | -117.26% | -109.33% | -154.03% | -98.92% |
| SG&A Expenses | -2.23% | 1.39% | 7.43% | 19.00% | 31.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.77% | 92.49% | 86.49% | 63.28% | 46.81% |
| Operating Income | -87.77% | -92.49% | -86.49% | -63.28% | -46.81% |
| Income Before Tax | -110.69% | -107.83% | -95.39% | -67.57% | -39.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -110.69% | -107.83% | -95.39% | -67.57% | -39.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.69% | -107.83% | -95.39% | -67.57% | -39.51% |
| EBIT | -87.77% | -92.49% | -86.49% | -63.28% | -46.81% |
| EBITDA | -87.85% | -92.58% | -86.57% | -63.31% | -46.83% |
| EPS Basic | -103.41% | -83.07% | -57.53% | -23.25% | 2.07% |
| Normalized Basic EPS | -103.45% | -83.09% | -57.51% | -21.69% | 3.29% |
| EPS Diluted | -103.41% | -83.07% | -57.53% | -22.75% | 2.45% |
| Normalized Diluted EPS | -103.45% | -83.09% | -57.51% | -21.69% | 3.29% |
| Average Basic Shares Outstanding | 3.93% | 12.99% | 23.55% | 34.29% | 41.99% |
| Average Diluted Shares Outstanding | 3.93% | 12.99% | 23.55% | 34.29% | 41.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |